Shionogi Selects QUMAS ComplianceSP on Microsoft SharePoint 2010 to Manage Quality Across the Organization

Shionogi Selects QUMAS ComplianceSP on Microsoft SharePoint 2010 to Manage 
Quality Across the Organization 
CORK, IRELAND -- (Marketwired) -- 04/09/13 --   QUMAS today announced
that Shionogi & Co., Ltd., a leading Japanese pharmaceutical company,
has selected QUMAS ComplianceSP(TM) software to manage its quality
Shionogi plans to deploy the QUMAS solution globally to key users
across the Clinical and Quality Assurance areas of the business.
QUMAS ComplianceSP will enable Shionogi to control Quality and
Manufacturing documents such as Standard Operating Procedures,
policies and manuals, in accordance with global regulatory
With the selection of QUMAS ComplianceSP, Shionogi can take advantage
of all the capabilities of Microsoft SharePoint 2010, while drawing
on the power of ComplianceSP for regulatory compliance management.
QUMAS extends the key SharePoint 2010 collaboration capability to
ensure full compliance with FDA CFR 21 Part 11 regulatory
"We have chosen QUMAS because ComplianceSP will provide us with
greater control over our quality and manufacturing documents and
ultimately create a more productive Shionogi," said Kohji Takeda,
Information Technology General Manager at Shionogi. "We were
impressed by the simple intuitive interface and QUMAS's extensive
knowledge of quality requirements and understanding of the SharePoint
"I am delighted that Shionogi has selected QUMAS ComplianceSP after
an extensive evaluation process involving a number of vendors," said
Kevin O'Leary, CEO QUMAS. "The selection of QUMAS will open up new
possibilities for Shionogi to speed up their regulatory compliance
processes and delivery of quality products." 
About Shionogi  
Shionogi has been developing innovative medicines that are essential
to people's health for over 130 years. 
Headquartered in Osaka, Japan, Shionogi & Co., Ltd. is a major
research-driven pharmaceutical company dedicated to placing the
highest value on patients. Shionogi's Research and Development
currently targets three therapeutic areas: Infectious Diseases, Pain,
and Metabolic Syndrome. The Company has provided such innovative
medicines as Crestor and Doripenem, which have been successfully
delivered to millions of patients. Shi
onogi is engaged in new
research areas such as allergy and cancer. For more details, please
About QUMAS 
QUMAS is the leader in Enterprise Compliance Solutions with more than
250 global customer deployments and two decades of experience helping
companies in highly regulated industries. QUMAS is a Gold Microsoft
Partner, and provides the QUMAS Compliance Platform on SharePoint
2010, Documentum, Oracle or SQL. For more information, visit 
All trade names, trademarks, and service marks are rightful property
of their respective owners. 
Caoimhe Kiely
VP Marketing 
+353 21 4915100 
Press spacebar to pause and continue. Press esc to stop.